FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385066837> ?p ?o ?g. }

• W4385066837 abstract "Background This study aimed to systematically evaluate the effects of different types and doses of pretreatment with P2Y 12 inhibitors in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) undergoing percutaneous coronary intervention (PCI). Methods Electronic databases were searched for studies comparing pretreatment with different types and doses of P2Y 12 inhibitors or comparison between P2Y 12 inhibitor pretreatment and nonpretreatment. Electronic databases included the Cochrane Library, PubMed, EMBASE, and Web of Science. Literature was obtained from the establishment of each database until June 2022. The patients included in the study had pretreatment with P2Y 12 inhibitors with long-term oral or loading doses, or conventional aspirin treatment (non-pretreatment). The primary endpoint was major adverse cardiac and cerebrovascular events (MACCEs) during follow-up within 30 days after PCI, which included determining the composite endpoints of cardiac death, myocardial infarction, ischemia-driven revascularization, and stroke. The safety endpoint was a major bleeding event. Results A total of 119,014 patients from 21 studies were enrolled, including 13 RCTs and eight observational studies. A total of six types of interventions were included—nonpretreatment (placebo), clopidogrel pretreatment, ticagrelor pretreatment, prasugrel pretreatment, double loading pretreatment (double loading dose of clopidogrel, ticagrelor, prasugrel) and P2Y 12 inhibitors pretreatment (the included studies did not distinguish the types of P2Y 12 inhibitors, including clopidogrel, ticagrelor, and prasugrel). The network meta-analysis results showed that compared to patients without pretreatment, patients receiving clopidogrel pretreatment ( RR = 0.78, 95% CI :0.66, 0.91, P &lt; 0.05) and double-loading pretreatment ( RR = 0.62, 95% CI :0.41, 0.95, P &lt; 0.05) had a lower incidence of MACCEs. There was no statistically significant difference in the incidence of major bleeding events among the six pretreatments ( P &gt; 0.05). Conclusions In patients with NSTE-ACS, pretreatment with P2Y 12 inhibitors before percutaneous intervention reduced the incidence of recurrent ischemic events without increasing the risk of major bleeding after PCI compared with nonpretreatment. Clopidogrel or double loading dose P2Y 12 inhibitors can be considered for the selection of pretreatment drugs." @default.
• W4385066837 created "2023-07-23" @default.
• W4385066837 creator A5007315342 @default.
• W4385066837 creator A5018218343 @default.
• W4385066837 creator A5024869850 @default.
• W4385066837 creator A5044356445 @default.
• W4385066837 creator A5047039553 @default.
• W4385066837 creator A5047374717 @default.
• W4385066837 creator A5054611487 @default.
• W4385066837 creator A5058974543 @default.
• W4385066837 creator A5064158500 @default.
• W4385066837 date "2023-07-19" @default.
• W4385066837 modified "2023-09-25" @default.
• W4385066837 title "Effect of pretreatment with a P2Y12 inhibitor in patients with non-ST-elevation acute coronary syndrome: a systematic review and network meta-analysis" @default.
• W4385066837 cites W1553345686 @default.
• W4385066837 cites W1569796594 @default.
• W4385066837 cites W1582447064 @default.
• W4385066837 cites W1936983670 @default.
• W4385066837 cites W1977260142 @default.
• W4385066837 cites W1993893954 @default.
• W4385066837 cites W1994844512 @default.
• W4385066837 cites W2002311059 @default.
• W4385066837 cites W2031896357 @default.
• W4385066837 cites W2053379248 @default.
• W4385066837 cites W2054817104 @default.
• W4385066837 cites W2075358198 @default.
• W4385066837 cites W2077520483 @default.
• W4385066837 cites W2084673482 @default.
• W4385066837 cites W2087554749 @default.
• W4385066837 cites W2096451143 @default.
• W4385066837 cites W2102951688 @default.
• W4385066837 cites W2109450652 @default.
• W4385066837 cites W2153107785 @default.
• W4385066837 cites W2166950143 @default.
• W4385066837 cites W2171071735 @default.
• W4385066837 cites W2433859828 @default.
• W4385066837 cites W2531269403 @default.
• W4385066837 cites W2550333256 @default.
• W4385066837 cites W2591640187 @default.
• W4385066837 cites W2754609628 @default.
• W4385066837 cites W2783309559 @default.
• W4385066837 cites W2803592997 @default.
• W4385066837 cites W2900273350 @default.
• W4385066837 cites W2934994918 @default.
• W4385066837 cites W3081991699 @default.
• W4385066837 cites W3087255278 @default.
• W4385066837 cites W3090005832 @default.
• W4385066837 cites W3105723579 @default.
• W4385066837 cites W3162195278 @default.
• W4385066837 cites W4200615065 @default.
• W4385066837 cites W4225013317 @default.
• W4385066837 cites W4376848313 @default.
• W4385066837 doi "https://doi.org/10.3389/fcvm.2023.1191777" @default.
• W4385066837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37539086" @default.
• W4385066837 hasPublicationYear "2023" @default.
• W4385066837 type Work @default.
• W4385066837 citedByCount "0" @default.
• W4385066837 crossrefType "journal-article" @default.
• W4385066837 hasAuthorship W4385066837A5007315342 @default.
• W4385066837 hasAuthorship W4385066837A5018218343 @default.
• W4385066837 hasAuthorship W4385066837A5024869850 @default.
• W4385066837 hasAuthorship W4385066837A5044356445 @default.
• W4385066837 hasAuthorship W4385066837A5047039553 @default.
• W4385066837 hasAuthorship W4385066837A5047374717 @default.
• W4385066837 hasAuthorship W4385066837A5054611487 @default.
• W4385066837 hasAuthorship W4385066837A5058974543 @default.
• W4385066837 hasAuthorship W4385066837A5064158500 @default.
• W4385066837 hasBestOaLocation W43850668371 @default.
• W4385066837 hasConcept C126322002 @default.
• W4385066837 hasConcept C127413603 @default.
• W4385066837 hasConcept C164705383 @default.
• W4385066837 hasConcept C168563851 @default.
• W4385066837 hasConcept C203092338 @default.
• W4385066837 hasConcept C2777028646 @default.
• W4385066837 hasConcept C2777628954 @default.
• W4385066837 hasConcept C2777698277 @default.
• W4385066837 hasConcept C2777849778 @default.
• W4385066837 hasConcept C2780400711 @default.
• W4385066837 hasConcept C2780645631 @default.
• W4385066837 hasConcept C2780890252 @default.
• W4385066837 hasConcept C35294091 @default.
• W4385066837 hasConcept C45393284 @default.
• W4385066837 hasConcept C500558357 @default.
• W4385066837 hasConcept C71924100 @default.
• W4385066837 hasConcept C78519656 @default.
• W4385066837 hasConceptScore W4385066837C126322002 @default.
• W4385066837 hasConceptScore W4385066837C127413603 @default.
• W4385066837 hasConceptScore W4385066837C164705383 @default.
• W4385066837 hasConceptScore W4385066837C168563851 @default.
• W4385066837 hasConceptScore W4385066837C203092338 @default.
• W4385066837 hasConceptScore W4385066837C2777028646 @default.
• W4385066837 hasConceptScore W4385066837C2777628954 @default.
• W4385066837 hasConceptScore W4385066837C2777698277 @default.
• W4385066837 hasConceptScore W4385066837C2777849778 @default.
• W4385066837 hasConceptScore W4385066837C2780400711 @default.
• W4385066837 hasConceptScore W4385066837C2780645631 @default.
• W4385066837 hasConceptScore W4385066837C2780890252 @default.
• W4385066837 hasConceptScore W4385066837C35294091 @default.
• W4385066837 hasConceptScore W4385066837C45393284 @default.
• W4385066837 hasConceptScore W4385066837C500558357 @default.

• next